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PROTEIN IMPRINTING BY MEANS OF 
ALGNATE-BASED POLYMERS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation in part of International 
Patent Application No. PCT/US 10/48718 filed Sep. 14, 2010 
and claims priority to U.S. Provisional Application No. 
61/241,994, filed Sep. 14, 2009, both of which are incorpo 
rated herein by reference. 
BACKGROUND 
The present invention relates to molecular imprinting poly 
mers, and, at least in Some embodiments, to novel calcium 
alginate polymer microcapsules and films, and their associ 
ated methods of use. 
A molecular imprinting polymer (“MIP) is generally a 
crosslinked polymeric network formed in the presence of an 
imprinting compound or “template molecule'. Such that the 
template molecule may be later removed, leaving a MIP that 
is able to recognize and bind to the template molecule via a 
complementary binding cavity. The release of the template 
molecule allows the MIP material to exhibit a selective 
“memory” with respect to the template molecule. This simu 
lates the typical molecular recognition of biological systems, 
such as antibodies or enzymes. MIPs tend to show a certain 
chemical affinity for the original template molecule and, con 
sequently, can be used to fabricate sensors, as catalysis, or for 
separation methods. 
Molecular imprinting has been successfully used to recog 
nize Small molecules, such as herbicides, metal ions, and 
amino acids. Thus, MIPS can be used as sensors, chromatog 
raphy beds, resins for separation processes, and analytical 
tools in enzyme-linked immunosorbent assays (“ELISA 
assays”). 
Heretofore, bio-macromolecules, such as antibodies and 
enzymes, have been employed for protein recognition pur 
poses. However, Such bio-macromolecules are sometimes 
difficult to find and/or produce. Thus, there is a need for 
receptor-like synthetic materials such as protein-imprinted 
polymers as Substitutes for natural receptors. 
However, the development of MIPs capable of recognizing 
macromolecules. Such as peptides and proteins, has met with 
many difficulties. The current approach to macromolecular 
imprinting generally involves the inclusion of a template 
molecule within a polymer formed from functional mono 
mers and crosslinking agents. However, macromolecular 
imprinting technologies heretofore have been generally 
incompatible with the diagnosis and recognition in many life 
Sciences applications, such as medical applications, food 
additives, or drug delivery, which require biocompatible or 
alimentary products. 
Alginate is generally a water soluble linear polysaccharide 
derived from brown algae and composed of alternating blocks 
of 1.4 linked C-L-guluronic and B-D-mannuronic acid resi 
dues (FIG.9). Physical networks are formed by the exchange 
of Sodium ions associated with the guluronic acid residues 
with divalent cations in the cross-linking solutions. The gulu 
ronic residues stack to form a characteristic egg-box struc 
ture. Dimerization of the alginate chains occurs through the 
divalent cations, as illustrated in FIG. 10, causing junctions 
between many chains to create a network structure. Although 
the biocompatibility and biodegradability of alginates has 
been documented, only limited studies have been done using 













ing. In fact, it is believed that each of the works to date have 
used the inverse Suspension method to produce alginate 
microcapsules, which involves the use of organic chemicals, 
Such us chloroform and hexane, that are incompatible with 
the medical and alimentary purposes. Similarly, Such 
attempts have been able to achieve at most a recognition of 
between about 0.46 mg to about 0.66 mg of the template 
molecule bovine serum albumin (“BSA) per gram of micro 
capsule. In addition, in these works, typically at least 48 hours 
has been required to achieve the release of the template mol 
ecule. 
SUMMARY 
The present invention relates to molecular imprinting poly 
mers, and, at least in Some embodiments, to novel calcium 
alginate polymer microcapsules and films, and their associ 
ated methods of use. 
The features and advantages of the present invention will 
be apparent to those skilled in the art. While numerous 
changes may be made by those skilled in the art, Such changes 
are within the spirit of the invention. 
DRAWINGS 
These drawings illustrate certain aspects of Some of the 
embodiments of the present invention, and should not be used 
to limit or define the invention. 
FIG. 1 illustrates a method of macromolecular imprinting 
according to one embodiment of the invention. 
FIG. 2 is a graph illustrating the amount of template mol 
ecule (BSA) released from the calcium alginate microcap 
Sules over a series of steps. The removal process was carried 
out in the following steps: 1. Mixing 3 h 4'/Continuous=1h 
42', 2. Mixing 2 h 30/Continuous=20', 3. Mixing 35'/Con 
tinuous=9', 4. Filtering, 5. Stored=1 d, 6. Stored=1, d. The 
initial amount of BSA removed was 21.86.18 mg. The final 
amount of BSA remaining was 2.1784 mg. for a total template 
removal of 90.04%. 
FIG. 3 is a graph illustrating the amount of template mol 
ecule (BSA) released from the calcium alginate microcap 
Sules over a series of steps. The removal process was carried 
out in the following steps: 1. Mixing 2h 28/Continuous-30'. 
2. Mixing 1 h 40/Continuous=10', 3. Mixing 40/Continu 
ous=8', 4. Filtering, 5. Stored=1 d, 6. Stored=1, d. The initial 
amount of BSA removed was 22.6153 mg. The final amount 
of BSA remaining was 2.91.45 mg, for a total template 
removal of 87.11%. 
FIG. 4 is a graph illustrating the amount of template mol 
ecule (BSA) released from the calcium alginate microcap 
Sules over a series of steps (total release, overnight mixing). 
The removal process was carried out in the following steps: 1. 
Mixing 2 h30/Continuous-30', 2. Mixing 4h 30'/Continu 
ous=22, 3. Mixing Overnight (12 h 48')./Continuous=13'. 
The initial amount of BSA removed was 22.4844 mg. The 
final amount of BSA remaining was 0 mg, for a total template 
removal of 100%. 
FIG. 5 is a graph illustrating the amount of template mol 
ecule (BSA) released from the calcium alginate microcap 
Sules over a series of steps (total release, 5 days of storage in 
DI water). The removal process was carried out in the follow 
ing steps: 1. Mixing 3 h 4/Continuous=1h 42. 2. Mixing 2 
h 30/Continuous=20', 3. Stored=3 d, 4. Stored=1 d, 5. 
Stored=ld. The initial amount of BSA removed was 23.3631 
mg. The final amount of BSA remaining was 0.0604 mg. for 
a total template removal of 97.74%. 
FIGS. 6A and 6B illustrate calibration curves to BSA. 
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FIG. 7 illustrates equipment used to the remove the tem 
plate molecule. For example, (1) and (3) peristaltic pumps; 
(2) reactor over an orbital shake rotator; (4) spectrophotom 
eter that operates in continuous; (5) thermostatic bath. 
FIGS. 8A and 8B illustrate recognition studies. 
FIG. 9 shows the chemical structure of alginate. 
FIG. 10 shows the coordination of alginate chains with 
divalent calcium. 
FIG. 11 shows the proposed ionic bond between histidine 
(an abundant amino acid in BSA) and alginate during the 
imprinting process. 
FIG. 12 shows the proposed repulsion between glutamic 
acid (an abundantamino acid in BSA) and alginate during the 
extraction process. 
FIG. 13 shows cumulative amount of BSA released from 
the imprinted alginate film during 0.05 M Tris-HCl (pH 7.5) 
with 1% CaCl rinse (hours 1, 2 and 3, shown in detail in inset) 
and during deionized water rinse (remaining timepoints) 
(n-3). Error bars represent +1 SD. Exponential fit to data is 
shown. 
FIG. 14 shows cumulative absorption of BSA into 
imprinted alginate films: (a) as an average (n=4) of four 
separate imprinting and recognition replicates and (b) single 
replicate demonstrating attainment of equilibrium after 6 
days. Error bars delineate +1 SD. 
FIG. 15 shows swelling of imprinted and non-imprinted 
alginate films. A similar degree of Swelling is seen in both 
types offilms, regardless of whether cross-linking occurred in 
the presence of BSA (n-6). 
While the present disclosure is susceptible to various modi 
fications and alternative forms, specific example embodi 
ments have been shown in the figures and are herein described 
in more detail. It should be understood, however, that the 
description of specific example embodiments is not intended 
to limit the invention to the particular forms disclosed, but on 
the contrary, this disclosure is to cover all modifications and 
equivalents as illustrated, in part, by the appended claims. 
DESCRIPTION 
The present invention relates to molecular imprinting poly 
mers, and, at least in Some embodiments, to novel calcium 
alginate polymer microcapsules, and their associated meth 
ods of use. 
In accordance with embodiments of the present invention, 
methods of the present invention may provide new means of 
protein imprinting and new techniques of generation of cal 
cium alginate-based polymer microcapsules which are com 
patible with life Sciences applications—such as medical diag 
nosis, detection in the food industry, or drug delivery— 
requiring biocompatible or alimentary products. One of the 
many potential advantages of the methods of the present 
invention, only some of which are herein disclosed, is that 
these methods may be capable of recognizing a higher quan 
tity of template molecule than existing technologies, with a 
simple formulation and with biocompatible materials. For 
example, the materials used in many embodiments of the 
invention, Sodium alginate and calcium chloride, may be 
totally biocompatible with the medical and food industry. 
Some embodiments of the invention provide macromo 
lecular imprinting using calcium alginate based polymer 
microcapsules via ionic gelation methods, requiring no addi 
tional chemicals other than Sodium alginate and calcium 
chloride, thereby allowing recognition of higher quantities of 
a template molecule, for example, as much as about 3 milli 
grams (“mg) of a template molecule. Such bovine serum 













ments, the microcapsules of the present invention may be able 
to bind from about 0.75 mg to about 3 mg of a template 
molecule per gram of microcapsule. In some embodiments, 
the microcapsules of the present invention may be able to bind 
from about 1 mg to about 3 mg of a template molecule per 
gram of microcapsule. In some embodiments, the microcap 
sules of the present invention may be able to bind from about 
2 mg to about 3 mg of a template molecule per gram of 
microcapsule. 
Ionic gelation generally refers to the process of formation 
of three dimensional ties/connections/junctions from macro 
molecular (polymer) chains by partial or total interaction of 
ionic charges, for example, positive ions and negative ions 
existing on the macromolecular chains or on branches, tethers 
and other molecular associations of the chains. Methods 
according to some embodiments of the invention may provide 
the release of the template molecule in as little as, for 
example, about 5 hours. 
In addition to being rapid and facile, methods of the present 
invention also may produce microcapsules with Substantially 
uniform pores and readily controlled size. The preparation 
process may be easily implemented and may take much less 
time than other, traditional polymerization methods. In some 
embodiments, the particle size may be controlled by varying 
the Viscosity of the liquid used to form the microcapsules. 
Without limiting the invention to a particular theory or 
mechanism of action, it is nevertheless currently believed that 
Sodium alginate has hydroxyl and carbonyl groups that allow 
dipole? dipole interaction and hydrogen bonding between 
alginate and a template molecule. After crosslinking between 
sodium alginate and Ca" ions, template molecules may be 
trapped inside the network and can be subjected to template 
removal and rebinding studies. To achieve good templated 
microcapsules, it may be preferred to bond the negatively 
charged carbonyl groups of alginate to the template molecule. 
For example, when the template molecule is BSA, it may be 
preferred to work below the isoelectric point of BSA (pl.-4.7) 
to allow the BSA to behave as positively charged and favor a 
stronger attractive electrostatic interaction between the BSA 
(positively charged) and the alginate (negatively charged). 
Similarly, when the template molecule is BSA, a solution 
comprising BSA may be prepared with a pH adjusted to about 
4.2 by hydrochloride solution. The alginate imprinted poly 
mers described herein anticipates the non-covalent binding of 
the carboxyl group of the alginate polymer with the template 
molecule functional groups. The low pH of the solution dur 
ing the crosslinking, which is below the pl of BSA, creates a 
positively charged, hydrophilic molecule, which non-co 
Valently interacts with the anionic alginate. In the case of 
BSA, at a pH of 4.2 ionic interactions may occur between the 
alginate and histidine, as shown in FIG. 11. Raising the pH 
above the pl of BSA will cause a repulsion effect between the 
negatively charged BSA and the negatively charged alginate 
and break the ionic interactions, as shown in FIG. 12 for 
glutamic acid. Alginate may also form hydrogen bonds with 
a template molecule, which will be unaffected by the modu 
lations in pH. 
Thus, methods of protein imprinting based on calcium 
alginate polymer microcapsules, via ionic gelation, requires 
only two reactants: Sodium alginate and calcium chloride, and 
may provide imprinting technology to new life-based appli 
cations. Furthermore, these methods may provide time Sav 
ings, in regard to the preparation of microcapsules, since the 
preparation time decrease significantly with respect to the 
traditional polymerization methods. 
As illustrated in FIG. 1, in one embodiment, a method of 
the present invention 100 may comprise preparing or provid 
US 8,940,394 B2 
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ing a template molecule. Such as a peptide or a protein 110. 
The method 100 may further comprise forming a microcap 
Sule comprising calcium alginate 120 (which may precede, 
follow, or occur Substantially simultaneously with preparing 
or providing a template molecule). For example, in one 
embodiment forming a microcapsule comprising calcium 
alginate may comprise the addition of an amount of sodium 
alginate to the template Solution to achieve a desired concen 
tration, followed by dropwise addition into a calcium chloride 
aqueous solution to obtain a template imprinted microcapsule 
120. The method may further comprise an additional step of 
removing the template molecule from the microcapsule 140. 
Complete extraction of the template molecule from the 
microcapsule may further require allowing time for micro 
capsule swelling 150. In some embodiments, removing the 
template molecule from the microcapsule 140 and allowing 
time for microcapsule swelling 150 may be successively 
repeated. Optionally, in Some embodiments, the imprinted 
microcapsules may then be used to recognize the template 
molecule. Either as a quality verification mechanism, or as a 
part of recognizing a target molecule, spectrophotometric 
measurements of the microcapsules may be performed 160. 
In contrast to previous work done on protein imprinting 
based on alginate microcapsules, which typically removed a 
BSA template molecule in about 48 hours through successive 
washes and agitation (discontinuous procedure), some 
embodiments of the present invention achieve a release of 
between about 87 and about 90% of the template molecule in 
only about 5 hours by combining discontinuous and continu 
ous procedures. For example, see the results presented in 
FIGS. 2 and 3. Removal of the template molecule from the 
microcapsules may proceed by breaking the bonds between 
the template molecules and the alginate chains. For example, 
the microcapsules may be washed using an elution solution. 
In some embodiments, the elution solution may include cal 
cium. For example, such a solution may comprise a mixture 
of about 1.0 wt. CaCl and Tris buffer solution (about 0.05 M. 
pH of about 7.4). Tris Base buffer solution may be commer 
cially available from ThermoFisher Scientific, Inc. of 
Waltham, Mass. It is believed that, due to the mechanism of 
formation of microcapsules by ionic gelation, the membrane 
of the microcapsules may grow from outside to inside by 
diffusion of cations of calcium throughout the membrane. A 
pH of about 7.4 may force the BSA to behave as negatively 
charged molecules, thus reducing the interactions between 
BSA and the negatively charged matrix of alginate. As has 
been shown in “Proteins incorporated into biomimetically 
prepared calcium phosphate coatings modulate their 
mechanical strength and dissolution rate.” by Liu et al. (Bio 
materials v 24, pp 65-70, 2003), the calcium of the elution 
Solution may interact with the template molecule and may 
force the template molecule to diffuse out the microcapsules. 
After removal of the template molecule, the microcapsules 
may be stored in deionized water in a refrigerated environ 
ment (e.g., from about 4 to about 8°C.) for a period of time to 
allow the Swelling process of the microcapsules. This time 
period may be a time sufficient to achieve a weight that does 
not change within about 0.05%, for example, from about 48 to 
about 96 hours). This may also permit the recovery of the 
original size of the microcapsules in the rebinding process, 
since the process of removal of the template molecule may 
cause the thickness of the membrane of the microcapsules to 
increase, and therefore may reduce the interior space inside 
the microcapsules, thereby reducing the space available 
inside the microcapsules to accommodate the template mol 













In some embodiments of the invention, total release of the 
template molecule from the microcapsules may require more 
than five hours. For example, see the results illustrated in FIG. 
4. It is believed that this may be due to the three cycles of 
mixing-extraction, the last taking place overnight. This may 
be undesirable; because of the calcium of the elution solution 
may create thicker microcapsule membranes with the greater 
time, which may result in not enough space inside of the 
microcapsules to achieve the rebinding process. Therefore, in 
Some embodiments, releasing the template molecule may 
comprise only two cycles of washing and maintaining the 
microcapsules in deionized water during 5 days, wherein the 
water is renewed daily by filtering. For example, see the 
results illustrated in FIG. 5. This may provide for the swelling 
process, while allowing the release of the remaining amount 
of template molecule without the presence of calcium. Since 
it is not necessary to achieve total release of the template 
molecule to attain a satisfactory recognition results, it may be 
preferable to use the removal process as illustrated in FIGS. 2 
and 3 to save time and allow enough space in the inside of the 
microcapsules for the rebinding process. In some embodi 
ments, at least about 75 to about 99% of the template mol 
ecule must be removed by washing so that the ensuing micro 
capsules can recognize it back. 
As an optional step, recognition of the template molecule 
may be verified through tests, such as spectrophotometer 
measurements. Without limiting the invention to a particular 
theory or mechanism of action, it is nevertheless currently 
believed that, since the calcium alginate microcapsules are 
biodegradable, they may disintegrate over time. Therefore, in 
Some embodiments, filtration of the Supernatant may occur 
before considering final results of absorbance for recognition 
of the protein. As has been shown in “Facile synthesis of 
polyanilinesodium alginate nanofibers.” by Yu et al. (Lang 
muir, V 22, pp. 3899-3905, 2006), alginate generally absorbs 
at about 280 nm. Additionally, the tests of alginate absorption 
may be followed by tests of control microcapsules. 
In other embodiments, the methods of the present disclo 
Sure may be used to synthesize molecularly imprinted algi 
nate films. Such films can be incorporated, for example, into 
biomolecular sensors. In certain embodiments, when BSA is 
used as a template molecule, there is improved binding of 
BSA to the imprinted film, as compared results using an 
aqueous imprinting method. In other embodiments, proteins 
varying in charge and size may be equilibrated with the 
imprinted alginate films to elucidate the mechanism of bind 
ing interaction. In other embodiments, the methods of the 
present disclosure may be used to synthesize a molecularly 
imprinted product. In certain embodiments, the product is a 
microcapsule or a film. 
To facilitate a better understanding of the present inven 
tion, the following examples of certain aspects of some 
embodiments are given. In no way should the following 




Calibration of the Protein 
A calibration absorbance/concentration was carried out in 
order to determine the concentration with time of the protein 
by means of spectrophotometer measurements. 
Calibration was based on about 20 mL of an about 10 
mg/mL protein solution as an initial Solution. Different Vol 
umes (Table 1) were taken from the initial solution, to obtain 
different known concentrations of protein, and were disposed 
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in micro centrifuge tubes, and all volumes were filled with 
deionized water until reaching about 1.5 mL. FIG. 6 show the 
calibration graphs. 
TABLE 1 
V, IL 1SOO 12OO 105O 900 750 675 600 
Conc., 10.0000 8.0000 7.0000 6.0000 5.0000 4.5000 4.0000 
mg/mL 
V, IL 255 225 187. SO 93.7S 46.88 23:44 
Conc., 1.7000 1.5000 1.2500 0.6250 0.3125 0.1563 
mg/mL 
Example 2 
Generation of BSA-Embedded Molecular Imprinted 
Calcium Alginate Microcapsules 
BSA was dissolved in deionized water (with pH adjusted to 
about 4.2 by hydrochloride Solution) until reaching a concen 
tration of about 10 mg BSA/mL. Then, sodium alginate pow 
der was added in the BSA solution until reaching a concen 
tration of about 2% wt. For example, suitable sodium alginate 
powder may be commercially available from SIGMA-ALD 
RICHR) of St. Louis, Mo. 
After the preparation of the solution, about 3 mL of the 
mixture was added dropwise into an about 2% wt. (alterna 
tively about 0.5 to about 8% wt. may be used) calcium chlo 
ride aqueous solution, thereby forming microbeads. For 
example, Suitable calcium chloride may be commercially 
available from EMD Chemicals, Inc. of Madison, Wis. (cal 
cium chloride dehydrate OmniPur Reagent Grade). The 
microbeads were kept in the cross-linking solution for about 
2 minutes (alternatively from about 5 to about 30 minutes, 
preferably from about 1 to about 10 minutes, preferably from 
about 1.5 to about 5 minutes). The microbeads were collected 
by filtration with a nylon filter membrane of about 0.2 
microns. 
A sample of the Supernatant was taken and analyzed to 
measure the loss in the whole process of the generation of the 
microcapsules. To know the exact weight of the microcap 
Sules, a Syringe was weighed before and after the generation 
of the microcapsules. 
The microbeads were then placed in a reactor for the pro 
cedure of releasing of the protein. 
Also, microcapsules without the protein (BSA) were pre 
pared for non-imprinted (NIP) control samples. The proce 
dure was the same as above. For the production of the NIP and 
control microcapsules, a specific amount of sodium alginate 
powder was dissolved into deionized water to form an about 
2% wt solution. 
Example 3 
Generation of Drops by Means of Extrusion 
The Solution (a mixture of alginate and the aqueous solu 
tion of protein) was extruded drop by drop through a needle 
using a sterile Syringe into the calcium chloride gelation 
Solution under stirring. This technique generated microcap 
sules with a particle size ranged between about 2 to about 3 
mm. Note, that it is possible to control the particle size by 
8 
varying the liquid viscosity. The alginate Solution's viscosity 
may be varied by changing the alginate Solution concentra 
tion, which may be used to control the size of the capsules. 
525 450 375 345 300 
3.SOOO 3.OOOO 2. SOOO 2.3OOO 2.OOOO 
11.72 5.86 2.93 1.47 0.73 
O.O782 O.O391 O.O195 O.OO98 0.0049 
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Example 4 
Removal of the Template 










achieve a Tris buffer solution of about 0.05 M. The pH of the 
buffer solution was set at about 7.4 by adding Hydrochloric 
Acid 1 N. For example, suitable Hydrochloric Acid 1N may 
be commercially available from ThermoFisher Scientific, 
Inc. of Waltham, Mass. Next, calcium chloride powder was 
added in the Tris Solution until reaching a concentration of 
about 1% wt. 
The microcapsules were placed in a beaker containing the 
elution solution: a mixture of about 1.0 wt. CaCl and Tris 
buffer solution (about 0.05 M. pH of about 7.4). The samples 
were briefly agitated. Then, the washing buffer was renewed 
by means of a continuous system until no additional template 
could be removed with this process (absorbance Zero). An 
illustration of the system is shown in the FIG. 7. After that, the 
whole process was repeated (mixing and continuous system). 
Finally, the process was repeated the last time, reducing the 
time of the mixing process. In some examples, the optimum 
stirring time may be between about 1.5 hours to about 2 hours, 
and the cycle time of agitation may be reduced down to about 
30-40 minutes of agitation in the last cycle. 
After the removal process of the templates, the microcap 
Sules were stored in a refrigerated environment (e.g., about 
4-8°C.) for several days (e.g., 2 days may be sufficient to 
allow the process of Swelling that will provide enough space 
inside of the capsules to achieve the rebinding process) in 
deionized water to allow the swelling process of the micro 
capsules. During this time, besides producing the Swelling 
process, any remaining amount oftemplate was released. The 
deionized water was changed daily by filtration, and the 
Supernatant was analyzed to know the release of the remain 
ing amount of template. 
The NIP and control microcapsules were subjected to the 
same process to maintain the same conditions that the MIP 
microcapsules. 
Example 5 
Recognition of the Protein 
A specific amount of BSA was dissolved in deionized 
water until reaching a concentration of about 1 mg BSA/mL. 
An accurately weighed amount of wet microcapsules (using 
filter paper to absorb the surface water) was placed in a 
centrifuge tube with about 40 mL of the about 1 mg/mL 
protein solution. The concentration of protein was evaluated 
with time by absorbance at about 280 nm using a spectropho 
tometer. The detection was continued until the change in 
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concentration of the Solution was undetectable, and the equi 
librium rebinding capacity was obtained. 
The process was repeated with the microcapsules without 
the protein, NIP, and the control microcapsules. The proce 
dure was the same as above. 
The results were compared for the MIP and NIP microcap 
Sules, providing an estimate of the amount of protein recog 
nized. The control microcapsules were used to know the 
absorbance of the alginate with time. For experiments with 
control microcapsules, microcapsules without protein were 
placed in just deionized water. The results are presented in 
Tables 2 and 3. 
TABLE 2 
MIP NIP MIP - NIP (mg)/mg 
BSA adsorption capsules 
Time (mg BSAfg caps) (mg BSAfg caps) (recognition) 
O OOOOO O.OOOO OOOOO 
5 h 7 1.7368 16046 O.1322 
2O SO 2.2868 1.9360 O.3508 
44 25 3.4940 2.86.13 O.6326 
71 h 17' 4.6OOO 3.6389 O.9611 
97 h O' S.S428 4.3863 1.1565 
118 h 14' 6.53O8 5.2050 1.3258 
141 S8' 7.4516 6.0903 1.3613 
1672" 8.3O31 6.9564 1.3467 
187 h 55 9.1284 7.6417 14867 
215 OO' 9.81.51 8.2950 1.S2OO 
TABLE 3 
MIP NIP MIP - NIP (mg)/g 
BSA adsorption capsules 
Time (mg BSAfg caps) (mg BSAfg caps) (recognition) 
O OOOOO O.OOOO OOOOO 
4 S2' O.9024 O.8078 O.O945 
2O SO 2.3644 2.1210 O.2434 
44 h 20 3.4763 3.0751 O4O12 
71 h9' 4.7453 3.7179 1.0274 
97 h O' 5.8790 4.4105 14685 
118 h 14' 6.9889 5.0367 19522 
141 S8' 8.4829 5.7887 2.6941 
1672" 9.5215 6.4954 3.0261 
187 h 55 10.2306 7.2S4O 2.9766 
215 O' 10.7398 7.8807 2.8591 
239 h 37 110757 8.5693 2.5064 
Example 6 
Gelation of Alginate MIPs 
Molecularly imprinted alginate hydrogel films were pre 
pared by cross-linking Sodium alginate in the presence of the 
template protein, bovine serum albumin (BSA). Deionized 
(DI) water was titrated to a pH of 4.2 with HCl (Fisher 
Scientific). To form the imprinting solution, 200 mg BSA 
(Sigma-Aldrich) was dissolved in 20 ml DI water at pH 4.2. 
Next, 0.4g Sodium alginate (Sigma-Aldrich) was added and 
stirred until dissolved. To form the control solution, 0.8 g. 
sodium alginate was added to 40 ml DI water at pH 4.2 and 
stirred until dissolved. Solutions were stored at 4° C. until 
SC. 
To cross-link films, 1.5 g of the alginate solutions was 
dispensed into a Petridish with a 5-cm diameter. The solution 













(CaCl) (Fisher Scientific) solution was pipetted over the 
alginate. The alginate was allowed to cross-link for 4 min. 
Upon exposure to the divalent CaCl2 solution, a semi 
opaque, mechanically stable film quickly formed. This film 
could be transferred with tweezers to the Tris buffer rinse 
Solution upon completion of the cross-linking. The thickness 
of the resulting films was approximately 1 mm. 
Example 7 
Release of Template from Alginate MIP 
After cross-linking, the films were rinsed and the release of 
BSA from the alginate rinse solutions was monitored. First 
the films were rinsed in a 0.05 M Tris-HCl (pH 7.4) solution 
with 1% CaCl, which was changed hourly for 3 h, and then 
the films were rinsed in DI water. The water was changed 
daily until a sample of the rinse solution had an absor 
bance~0.003 OD, as measured at 280 nm on a Lambda 10 
UV-Vis spectrophotometer (Perkin Elmer). A calibration 
curve developed from a serial dilution of a 1 mg/ml solution 
of BSA was used to calculate the amount of BSA in each rinse 
Solution. 
The release of BSA from the rinse solutions is shown in 
FIG. 13. Consistently, approximately 10 mg BSA was 
detected in the rinse solutions, while 15 mg BSA was in the 
polymer Solution prior to cross-linking. A significant portion 
of the BSA is likely removed during the cross-linking pro 
cess, since cross-linking induces significant de-Swelling of 
the gel. As the solvent is expelled from the polymer when it 
crosslinks, the template molecule is also pushed out of the 
film. 
Example 8 
Recognition of Alginate MIP 
Recognition studies were performed by incubating cross 
linked and rinsed alginate films with BSA solutions. A 1 
mg/ml Solution of BSA in deionized water was prepared, and 
50 ml of the solution was added to a 50 ml polypropylene 
centrifuge tube with the alginate film. The samples were 
placed on a rotary mixer and the Solution was sampled daily 
to read the absorbance of the solution at 280 nm using a 
UV-Vis spectrophotometer (Lambda 10, PerkinElmer) until 
equilibration was reached. To calculate the absorption of BSA 
at equilibrium, equation (1) was used: 
(Co - C)V (1) 
where Q is the equilibrium absorption, Co is the initial 
protein concentration, C., is the final concentration of protein 
at equilibrium, V is the volume of the protein solution and W 
is the weight of the polymer incubated in the solution. 
Imprinting efficiency, IE, can then be defined as shown in 
equation (2): 
(2) QMIP 
The interaction between an imprinted polymer and the 
template molecule can be compared to an antigen-antibody 
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binding interaction. This association and dissociation of the 
complex can be symbolized as: 
(3) 
where P is the concentration of unbound antibody, IL is the 
concentration of unbound ligand, IPL is the concentration of 
protein and ligand which are bound, k, is the forward reaction 
rate and k, is the reverse reaction rate of association. A stan 
dard metric for the assessment of the strength of this interac 
tion is the dissociation constant, or K. One can also define 
the equilibrium binding constant, K, as shown in equation 
(4): 
K. = , = , = IP (4) 
ea k, K, PIL) 
The dissociation constant was used to compare the strength of 
the interaction between the polymer film and the template 
molecule with traditional antibody-antigen interactions. In 
our case, P becomes the concentration of possible binding 
sites in the polymer film, L is the concentration of template 
in solution and PL is the concentration oftemplate absorbed 
and presumably bound in the polymer film, all observed at 
equilibrium. 
Preferential absorption of the imprinted BSA template was 
demonstrated through equilibrium recognition studies. The 
calculated values for Qe (in units of mg/gpolymer) are shown 
in Table 4. The amount of BSA absorbed was 6.4 mg/g poly 
mer, which compares favorably to previously reported values 
of approximately 0.3 mg/g polymer. Using the equation for 
the dissociation constant, the K of the BSA imprinted algi 
nate polymer was found to be 6 mM. This is several orders of 
magnitude above the dissociation constants found for Small 
molecule imprinted polymers, and above the reported binding 
affinity of an epitope approach to BSA imprinting, which 
indicates a weaker interaction between the polymer matrix 
and the protein. However, these results are similar to the 
results of polymeric imprinting BSA in aqueous media, 
which have demonstrated adsorption capacities on the order 
of 5 mg/g polymer, and Surface imprinted microbeads, with 
demonstrated adsorption capacities of 1.4 mg/gpolymer. The 
absorption of BSA is shown as a function of time in FIG. 14. 
A single replicate (FIG. 14b) attains equilibrium within 6 
days. Since the recognition experiment occurred in water, 
Ca" ions will be exchanged and the film will slowly degrade, 
causing the loss of recognition sites for BSA over time. This 
gradual degradation accounts for the decrease in absorption 
of BSA at longer time points. The time to reach equilibrium 
varied between 3 and 6 days. 
TABLE 4 
Qe of alginate films imprinted for BSA (MIP) 
and non-imprinted (NIP), average of four recognition 
experiments(n = 3 for each experiment 
Sample Q (mg/gpolymer) Imprinting Efficiency (IE) 















Specificity of Alginate MIP 
Proteins with varying molecular mass and isoelectric 
points (pl), provided in Table 5, were selected for determining 
the specificity of the alginate MIP for BSA (all proteins 
obtained from Sigma-Aldrich). Ovalbumin is a protein found 
in abundance in egg white, with a pi similar to BSA but with 
a lower molecular mass. It is expected that ovalbumin would 
bind non-specifically to any cavities formed in the BSA 
imprinted films. Hemoglobin (Hb) is the oxygen-transporting 
protein found in red blood cells. The bovine hemoglobin 
selected for these experiments has a molecular mass similar to 
BSA, but with a higher pl. In water, Hb should be close to 
neutral in charge. Human serum albumin (HSA) has a similar 
molecular mass and pl, but a different structure from that of 
BSA 
Alginate hydrogels used in the selectivity experiments 
were prepared as described above. Films were then incubated 
in 1 mg/ml Solutions of the competitor proteins selected and 
the absorbance of each solution was measured daily. The 
absorbance of the ovalbumin solutions were read on the 
Lambda 10 UV-Vis spectrophotometer in a cuvette at 280 nm. 
The absorbance of the Hb solutions was read on the same 
spectrophotometer at 405 nm. The absorbance of the HSA 
samples was read using a microplate reader (Synergy HT 
Biotek) at a wavelength of 280 nm. 
To analyze the selectivity of the alginate hydrogels for the 
template protein, the selectivity, C., was calculated using 
equation (5): 
(5) Katemplate 
C. : - Ka.competit 
where the equilibrium affinity constant is calculated using 
equation (4). 
TABLE 5 
Molecular Mass and Isoelectric Points of 
Proteins Used In the Selectivity Studies 
Molecular Hydrodynamic 
Protein Mass (kDa) pI radius (A) 
BSA 66 4.9 120 
Ovalbumin 45 4.7 27.4 
HSA 69 4.8 34.5 
Hb 68 6.8 55 
The results of the specificity experiments reveal that the 
imprinting efficiency of the BSA imprinted alginate films is 
significantly lower for the selected proteins than for the BSA 
itself, meaning that the amount protein absorbed by the MIP 
is similar to the amount of protein absorbed by the NIP for 
ovalbumin, Hb and HSA, as shown in Table 6. The selectivity 
of the films, calculated using equation (6), is insufficient for 
ovalbumin and Hb. In the case of ovalbumin, precipitation of 
the polymer occurred during the course of the experiment, 
making the standard specificity calculation inaccurate—a 
significant amount of the protein was simply precipitated out 
of solution, rather than absorbed into the imprinted alginate 
film. The imprinting efficiency results demonstrate this more 
clearly, in that the MIP does not absorb more OVA than the 
NIP. In the case of Hb, it is likely that the predominance of 
positively charged residues on the protein, at the pH under 
US 8,940,394 B2 
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test, allows the Hb to non specifically bind to the anionically 
charged alginate. This experiment demonstrates that though 
the molecular imprinting appears to be a real effect, the appli 
cation of the films in physiological conditions may be limited 
due to significant non-specific binding of positively charged 
species in physiological conditions. 
TABLE 6 
Selectivity Comparison (Films imprinted with BSA, exposed 
to either BSA or a competitive molecule (n = 3 
Protein C. IE 
Ovalbumin 1.6 x 10 1.1 
Hb 1.4 x 107 1.O 
HSA -1.0 x 10 1.1 
Example 10 
Swelling of Alginate MIP 
Since the degree of swelling and, therefore, the pore size, of 
the alginate hydrogels may be affected by the imprinting 
process, the Swelling of the films was monitored after synthe 
sis. The cross-linked polymer films, imprinted as described 
above, using non-imprinted polymer films cross-linked with 
out BSA as controls, were weighed immediately after syn 
thesis. The films were incubated in deionized water, removed 
from the incubation solution each day, blotted to remove 
excess solvent and weighed. 
The degree of Swelling, Q, was calculated using equation 
(6): 
(6) 
where W is the as-synthesized initial weight, and W, is the 
weight at time t. 
The swelling behavior of the imprinted alginate films was 
similar to that of the non-imprinted alginate films. As shown 
in FIG. 15, the MIP and NIP films present similar in the 
degree of Swelling and Swelling kinetics. The existence of 
similar Swelling kinetics in both the imprinted and non-im 
printed films indicates that the mesh size of the alginate films 
is Sufficiently large that the presence of imprinted cavities 
within the film does not enhance the transport of solvent into 
the film, and the effect of the imprinting process upon the 
Swelling behavior of the alginate films is minimal. 
Thus, we have found that the binding of BSA to alginate 
films is comparable, and in Some cases improved, over large 
macromolecular imprinted results previously cited in the lit 
erature. Although in the experiments presented here the 
equilibration was reached after 6 days, this is due to the 
considerable thickness of the films. If the films were reduced 
in thickness from 1 mm to 1 um, the time scale should be 
reduced from days to minutes, as has been demonstrated with 
alginate microbeads. Reduction of the film thickness can be 
achieved through spincoating and other micro and nanofab 
rication techniques. Although the imprinted versus non-im 
printed films absorb the competitive proteins equally, some 
proteins exhibit high degrees of non-specific binding to the 
alginate films. This is due to the ionic interactions between a 
positively charged molecule and the negatively charged algi 
nate—despite the presence of binding cavities preferential for 














which has a higher pl. In addition to a careful design of the 
functional interactions, it is clear from these results there 
must also be some consideration for avoidance of non-spe 
cific binding, perhaps by incorporation of poly(ethylene gly 
col) (PEG), which could shield the bulk polymer from non 
specific binding. Little attention has been paid to this issue in 
literature, possibly since often these materials will be used for 
chromatography applications where the composition of the 
Solution is more controlled in comparison to biomedical 
applications where the physiological environment is quite 
complex. 
Therefore, the present invention is well adapted to attain 
the ends and advantages mentioned as well as those that are 
inherent therein. The particular embodiments disclosed 
above are illustrative only, as the present invention may be 
modified and practiced in different but equivalent manners 
apparent to those skilled in the art having the benefit of the 
teachings herein. Furthermore, no limitations are intended to 
the details of construction or design herein shown, other than 
as described in the claims below. It is therefore evident that 
the particular illustrative embodiments disclosed above may 
be altered or modified and all such variations are considered 
within the scope and spirit of the present invention. While 
compositions and methods are described in terms of "com 
prising.” “containing, or “including various components or 
steps, the compositions and methods can also “consist essen 
tially of or “consist of the various components and steps. 
All numbers and ranges disclosed above may vary by some 
amount. Whenever a numerical range with a lower limit and 
an upper limit is disclosed, any number and any included 
range falling within the range is specifically disclosed. In 
particular, every range of values (of the form, “from about a to 
about b,” or, equivalently, “from approximately a to b,” or, 
equivalently, “from approximately a-b') disclosed herein is 
to be understood to set forth every number and range encom 
passed within the broader range of values. Also, the terms in 
the claims have their plain, ordinary meaning unless other 
wise explicitly and clearly defined by the patentee. Moreover, 
the indefinite articles 'a' or “an as used in the claims, are 
defined herein to mean one or more than one of the element 
that it introduces. If there is any conflict in the usages of a 
word or term in this specification and one or more patent or 
other documents that may be incorporated herein by refer 
ence, the definitions that are consistent with this specification 
should be adopted. 
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What is claimed is: 
1. A method comprising: 
providing a first Solution comprising a template molecule: 
combining Sodium alginate with the first solution to form a 
second solution: 
combining calcium chloride with the second Solution 
thereby forming a microcapsule comprising calcium 
alginate and the template molecule, wherein the first and 
second solution are free of organic solvents such that 
formation of the microcapsule is performed in the 
absence of organic solvents; 
removing the template molecule from the microcapsule to 
form an imprinted microcapsule; and 
retaining the imprinted microcapsule. 
2. The method of claim 1 wherein combining calcium 
chloride with the second solution comprises extruding the 








3. The method of claim 1, wherein the second solution does 
not comprise a Surfactant. 
4. The method of claim 1, wherein the second solution 
consists essentially of a template molecule and sodium algi 
nate. 
5. The method of claim 1, wherein the template molecule is 
a peptide or a protein. 
6. The method of claim 1, wherein the template molecule is 
bovine serum albumin. 
7. The method of claim 1, wherein the first solution has a 
pH between about 4.0 and about 4.5. 
8. The method of claim 1, wherein removing the template 
molecule from the microcapsule comprises breaking bonds 
between the template molecule and the calcium alginate. 
9. The method of claim8, wherein breaking bonds between 
the template molecule and the calcium alginate comprises 
washing the microcapsules with an elution solution and 
allowing time for Swelling of the microcapsules. 
10. The method of claim 9, wherein the elution solution 
comprises calcium. 
11. The method of claim 9, wherein the elution solution has 
a pH between about 7.2 and about 7.6. 
12. The method of claim 9, whereinwashing the microcap 
sules occurs for a period of time between about 1 and about 5 
hours. 
13. The method of claim 9, wherein allowing time for 
Swelling of the microcapsules occurs for a period of time 
between about 1 and about 4 days. 
14. The method of claim 9, wherein the microcapsules are 
immersed in deionized water while allowing time for swell 
ing of the microcapsules. 
k k k k k 
